Author

Xiaoyu Liu

Institutions: Chongqing University, Chongqing Cancer Hospital

Observed institutions: Chongqing University, Chongqing Cancer Hospital

ORCID: 0009-0001-2877-5575

Observed ORCID: 0009-0001-2877-5575

OpenAlex ID: A5141226990

Neoadjuvant Pertuzumab Biosimilar HLX11 versus Reference Pertuzumab for Early-Stage or Locally Advanced Breast Cancer: A Phase III Equivalence Trial

2026 · Jin Zhang, Jinhai Zhu, et al. · Clinical Cancer Research

Abstract PR005: JAB-BX600, a first-in-class EGFR-directed antiboEdy drug conjugate delivering a novel KRAS G12D inhibitor

2026 · Peng Wang, Fangjie Liu, et al. · Clinical Cancer Research

Abstract A015: JAB-BX600, a first-in-class EGFR-directed antiboEdy drug conjugate delivering a novel KRAS G12D inhibitor

2026 · Peng Wang, Fangjie Liu, et al. · Clinical Cancer Research

Works count: 3

Citation count:

H-index:

I10-index: